HSP110 promotes colorectal cancer growth through STAT3 activation-Reference-Cited by-同舟云学术

HSP110 promotes colorectal cancer growth through STAT3 activation

Published:2016-11-07 Issue:16 Volume:36 Page:2328-2336
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Berthenet K,Bokhari A'dem,Lagrange A,Marcion G,Boudesco C,Causse S^ORCID,De Thonel A,Svrcek M,Goloudina A R,Dumont S,Hammann A,Biard D S,Demidov O N,Seigneuric R,Duval A^ORCID,Collura A,Jego G,Garrido C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/onc2016403.pdf

Reference25 articles.

1. Jego G, Hazoume A, Seigneuric R, Garrido C . Targeting heat shock proteins in cancer. Cancer Lett 2013; 332: 275–285.

2. Saibil H . Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol 2013; 14: 630–642.

3. Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, Hrstka R et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep 2009; 21: 1235–1241.

4. Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med 2011; 17: 1283–1289.

5. Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P . Hsp110 is a bonafide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. J Biol Chem 2013; 288: 21399–21411.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer;Journal of Experimental & Clinical Cancer Research;2024-07-11

2. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma;Leukemia;2024-06-21

3. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma;Journal of Experimental & Clinical Cancer Research;2024-05-22

4. Heat Shock Proteins, a Double-Edged Sword: Significance in Cancer Progression, Chemotherapy Resistance and Novel Therapeutic Perspectives;Cancers;2024-04-14

5. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation;Cancers;2024-03-31